(S)-ethyl 3-cyanopentanoate | 1316290-57-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-ethyl 3-cyanopentanoate
• 英文别名: ethyl (3S)-3-cyanopentanoate
• CAS: 1316290-57-9
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: HOHSJEOLBDROAJ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 (S)-ethyl 3-cyanopentanoate 在 titanium(IV) tetraethanolate 、 乙二醇 作用下， 反应 118.0h， 以84%的产率得到(S)-methyl 3-cyanopentanoate
  参考文献：
  名称：

  Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases

  摘要：

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.

  DOI：

  10.1021/jo302484p
• 作为产物：
  描述：

  丙酰乙酸乙酯 在 四(三苯基膦)钯 、 Lactobacillus brevis alcohol dehydrogenase 、 Saccharomyces pastorianus old yellow enzyme, isoenzyme OYE₂ 、 四甲基氢氧化铵 、 烟酰胺腺嘌呤双核苷酸磷酸盐 、 异丙醇 作用下， 以 aq. phosphate buffer 、 正庚烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.75h， 生成 (S)-ethyl 3-cyanopentanoate
  参考文献：
  名称：

  Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases

  摘要：

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.

  DOI：

  10.1021/jo302484p